Low neutrophil alkaline phosphatase score is a new aspect of calreticulin-mutated myeloproliferative neoplasms

Calreticulin ( CALR ) and JAK2 -V617F gene mutations, which are major genetic mutations in patients with primary myelofibrosis (PMF) and essential thrombocythemia (ET), exert different effects on the clinical features and outcomes of these diseases. We analyzed 88 and 9 patients with ET and PMF, res...

Full description

Saved in:

Bibliographic Details
Published in:	SpringerPlus Vol. 5; no. 1; p. 1146
Main Authors:	Kondo, Toshinori, Tasaka, Taizo, Tomioka, Nanako, Sano, Fuminori, Tokunaga, Hirotoshi, Suemori, Shin-ichiro, Tsujioka, Takayuki, Matsuhashi, Yoshiko, Nakanishi, Hidekazu, Wada, Hideho, Tohyama, Kaoru, Sugihara, Takashi
Format:	Journal Article
Language:	English
Published:	Cham Springer International Publishing 22-07-2016 Springer Nature B.V
Subjects:	Humanities and Social Sciences Medicine multidisciplinary Science Science (multidisciplinary) Essential thrombocythemia Calreticulin Janus kinase 2 Myeloproliferative neoplasms Alkaline phosphatase score
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Calreticulin ( CALR ) and JAK2 -V617F gene mutations, which are major genetic mutations in patients with primary myelofibrosis (PMF) and essential thrombocythemia (ET), exert different effects on the clinical features and outcomes of these diseases. We analyzed 88 and 9 patients with ET and PMF, respectively, and determined the differences in the clinical characteristics of ET patients with JAK2 -V617F compared with CALR mutations. The frequency of the JAK2 -V617F and CALR mutations were 64 and 22 %, respectively. Patients with CALR mutations were younger, had a lower white blood cell count, and had a lower rate of thrombotic events than patients with the JAK2 mutation. The neutrophil alkaline phosphatase (NAP) score of 16 patients with CALR mutations was significantly lower than the normal controls, which was mainly due to the high proportion of NAP-negative neutrophils. This is the first report to show an association between CALR mutations in patients with myeloproliferative neoplasms (MPN) and the NAP score. Although the mechanism is unclear, the NAP score could be a useful and reliable biochemical marker to discriminate the mutational status of MPN patients. Further investigation is warranted to determine whether these characteristics contribute to the pathogenesis of MPN and the NAP score.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	2193-1801 2193-1801
DOI:	10.1186/s40064-016-2829-6